Randomized Control Trial Comparing Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
To compare the efficacy of rifaximin and placebo in the treatment of bowel dysfunction as measured by MSKCC Bowel Function Instrument (BFI score) in patients following Anterior Resection (AR) or Sphincter Preserving Surgery (SPS) for rectal cancer.
1 year
No
Philip Paty, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
11-045
NCT01345175
April 2011
April 2014
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
Memorial Sloan-Kettering Cancer Center at Basking Ridge | Basking Ridge, New Jersey 07920 |
Memorial Sloan-Kettering Cancer Center Commack | Commack, New York 11725 |
Memorial Sloan-Kettering Cancer Center Sleepy Hollow | Sleepy Hollow, New York 10591 |